Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 173 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... May 25, 2022 Cancer in My Community: Obstacles to Caring for People With Cancer... November 23, 2020 Cancer Patient’s Appetite Increases And His Blood Pressure Lowers After A... September 24, 2019 The EPA’s Limitations On This Toxic Pesticide Put Children At Risk... February 5, 2021 Load more HOT NEWS Hero Nanny Permanently Injured While Saving 2-Year-Old From Speeding Car About... Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with... 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with...
